KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xylem (XYL) Shares Issued (2016 - 2025)

Xylem (XYL) has 15 years of Shares Issued data on record, last reported at $9.0 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 800.0% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $20.0 million, down 70.15%, while the annual FY2025 figure was $20.0 million, 70.15% down from the prior year.
  • Shares Issued reached $9.0 million in Q4 2025 per XYL's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Shares Issued topped out at $33.0 million in Q2 2023 and bottomed at $1.0 million in Q1 2022.
  • Average Shares Issued over 5 years is $8.8 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Shares Issued: surged 1550.0% in 2023, then crashed 94.12% in 2024.
  • A 5-year view of Shares Issued shows it stood at $4.0 million in 2021, then tumbled by 50.0% to $2.0 million in 2022, then soared by 750.0% to $17.0 million in 2023, then plummeted by 94.12% to $1.0 million in 2024, then soared by 800.0% to $9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $9.0 million in Q4 2025, $3.0 million in Q3 2025, and $2.0 million in Q2 2025.